<DOC>
	<DOCNO>NCT00976365</DOCNO>
	<brief_summary>The purpose study obtain evidence test article efficacy Metastatic Breast Cancer patient . The average change baseline post-treatment evaluation global health/quality life ( QoL ) subscale assess self-administered European Organization Research Treatment Cancer Quality Life Questionnaire - Core 30 ( EORTC-QLQ-C30 ) .</brief_summary>
	<brief_title>Evaluation Safety Efficacy THL-P Metastatic Breast Cancer</brief_title>
	<detailed_description>The test article extract many natural herbal , component show anti-tumor activity . A study 2004 show test article could strong immunomodulatory effect antigen-stimulated proliferation response ( PR ) peripheral blood mononuclear cell ( PBMC ) T-cells recurrent aphthous ulceration ( RAU ) patient suggest might potential immunoceutical agent treatment RAU . Subsequent study 2005 also suggest test article potential immunoceutical agent treatment RAU result show could modulate antigen-stimulated cytokine production T-cells isolate RAU patient . Another study 2005 show test article also broad-range tumor kill function provide molecular basis underlie therapeutic activity . It also suggest study could potential promise cancer therapeutic preventive agent . The aim current study explore safety efficacy investigational product 20 ml , 3 time per day ( daily dose : 60 ml ) total 24 week patient metastatic breast cancer refractory conventional treatment modality .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Confirmed breast cancer clinical evidence . Life expectancy least 4 week . Any Uncontrolled infection . Lupus erythematosus . Malignant tumor .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>